Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Campone, Mario"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hortobagyi GN; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Stemmer SM; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Burris HA; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Yap YS; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Sonke GS; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Paluch-Shimon S; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Campone M; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Blackwell KL; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., André F; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Winer EP; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Janni W; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Verma S; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Conte P; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Arteaga CL; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Cameron DA; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Petrakova K; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Hart LL; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Villanueva C; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Chan A; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Jakobsen E; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Nusch A; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Burdaeva O; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Grischke EM; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Alba E; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Wist E; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Marschner N; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Favret AM; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Yardley D; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Bachelot T; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Tseng LM; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Blau S; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Xuan F; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Souami F; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Miller M; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Germa C; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., Hirawat S; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.)., O'Shaughnessy J; From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).
Publikováno v:
The New England journal of medicine [N Engl J Med] 2016 Nov 03; Vol. 375 (18), pp. 1738-1748. Date of Electronic Publication: 2016 Oct 07.